报价延迟最少15分钟:2026/09/02 20:20 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
74.59 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-2.69/-2.80
|
|
企业价值
6.73B
|
| 资产负债 |
|
每股账面净值
11.61
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
191.00K
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease. |
